Peter Greenleaf
CIK 1363683 · Chief Executive Officer · last filed 2026-11-04
Peter Greenleaf is a Chief Executive Officer who has filed 62 SEC Form 4 insider transactions across 11 companies since 2007. The most recent filing, for ALT, was dated Nov 4, 2026. Across all open-market trades the lifetime net is −$7.6M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $32.0M across reported positions. 8 SEC filings were submitted jointly with Cerecor Inc.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
AUPH price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
#140, 14315-118 AVENUE
EDMONTON T5L 4S6
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ALT | Director | — | $2.03 | — | $0 | 1 | 2026-11-04 |
| PTHS | Director | 23,087 | $9.52 | $219.8K | -$54.4K | 5 | 2026-10-06 |
| AUPH | Chief Executive Officer | 1,941,269 | $16.36 | $31.76M | -$4.22M | 10 | 2026-03-03 |
| ANTARES PHARMA, INC. (ATRS) Delisted | Director | 79,645 | $5.59 | $445.2K | $0 | 4 | 2021-06-14 |
| Avalo Therapeutics, Inc. (CERC) Delisted | Chief Executive Officer | 112,500 | $2.93 | $329.6K | $0 | 3 | 2019-10-03 |
| EYEG | Director | — | $33.98 | — | $0 | 2 | 2019-02-05 |
| Avalo Therapeutics, Inc. (CERCW) Delisted | Chief Executive Officer | 412,500 | — | — | $49.8K | 4 | 2018-05-21 |
| Sucampo Pharmaceuticals, Inc. (SCMP) Delisted | Chief Executive Officer | 0 | — | — | -$3.37M | 16 | 2018-02-13 |
| MSTX | Director | — | $11.80 | — | $0 | 3 | 2017-01-23 |
| SYNLOGIC, INC. (MIRN) Delisted | Director | — | — | — | $0 | 3 | 2016-09-06 |
| MEDI | SVP, Sales and Marketing | — | $34.99 | — | $0 | 2 | 2007-06-19 |
Recent Filings
62 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-11-04 | ALT | Grant (A) | — | $0 | EDGAR |
| 2026-10-06 | PTHS | Sell (S) | −797 | -$16.9K | EDGAR |
| 2026-07-07 | PTHS | Sell (S) | −797 | -$20.8K | EDGAR |
| 2026-05-11 | AUPH | Notice (144) | −3,136,201 | -$49.68M | EDGAR |
| 2026-04-06 | PTHS | Sell (S) | −797 | -$16.7K | EDGAR |
| 2026-04-01 | PTHS | Grant (A) | +25,478 | $0 | EDGAR |
| 2026-03-03 | AUPH | Mixed | +95,513 | -$1.43M | EDGAR |
| 2026-02-23 | AUPH | Tax (F) | −100,171 | -$1.44M | EDGAR |
| 2026-01-05 | AUPH | Mixed | +52,215 | -$1.81M | EDGAR |
| 2025-07-07 | PTHS | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.